|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bezjak A, Tu D, Seymour L, Clark G,
Trajkovic A, Zukin M, Ayoub J, Lago S, de Albuquerque Ribeiro R,
Gerogianni A, et al; National Cancer Institute of Canada Clinical
Trials Group Study BR.21. Symptom improvement in lung cancer
patients treated with erlotinib: Quality of life analysis of the
National Cancer Institute of Canada Clinical Trials Group Study
BR.21. J Clin Oncol. 24:3831–3837. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nguyen KS, Kobayashi S and Costa DB:
Acquired resistance to epidermal growth factor receptor tyrosine
kinase inhibitors in non-small-cell lung cancers dependent on the
epidermal growth factor receptor pathway. Clin Lung Cancer.
10:281–289. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eramo A, Lotti F, Sette G, Pilozzi E,
Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C and De
Maria R: Identification and expansion of the tumorigenic lung
cancer stem cell population. Cell Death Differ. 15:504–514. 2008.
View Article : Google Scholar
|
|
5
|
Levina V, Marrangoni A, Wang T, Parikh S,
Su Y, Herberman R, Lokshin A and Gorelik E: Elimination of human
lung cancer stem cells through targeting of the stem cell
factor-c-kit autocrine signaling loop. Cancer Res. 70:338–346.
2010. View Article : Google Scholar
|
|
6
|
Sun FF, Hu YH, Xiong LP, Tu XY, Zhao JH,
Chen SS, Song J and Ye XQ: Enhanced expression of stem cell markers
and drug resistance in sphere-forming non-small cell lung cancer
cells. Int J Clin Exp Pathol. 8:6287–6300. 2015.PubMed/NCBI
|
|
7
|
Hassan SS, Romero R, Pineles B, Tarca AL,
Montenegro D, Erez O, Mittal P, Kusanovic JP, Mazaki-Tovi S,
Espinoza J, et al: MicroRNA expression profiling of the human
uterine cervix after term labor and delivery. Am J Obstet Gynecol.
202:80.e1–80.e8. 2010. View Article : Google Scholar
|
|
8
|
Geng Q, Fan T, Zhang B, Wang W, Xu Y and
Hu H: Five microRNAs in plasma as novel biomarkers for screening of
early-stage non-small cell lung cancer. Respir Res. 15:1492014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang H, Wang L, Wu Z, Sun R, Jin H, Ma J,
Liu L, Ling R, Yi J, Wang L, et al: Three dysregulated microRNAs in
serum as novel biomarkers for gastric cancer screening. Med Oncol.
31:2982014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nian W, Ao X, Wu Y, Huang Y, Shao J, Wang
Y, Chen Z, Chen F and Wang D: miR-223 functions as a potent tumor
suppressor of the Lewis lung carcinoma cell line by targeting
insulin-like growth factor-1 receptor and cyclin-dependent kinase
2. Oncol Lett. 6:359–366. 2013.PubMed/NCBI
|
|
11
|
Miller TE, Ghoshal K, Ramaswamy B, Roy S,
Datta J, Shapiro CL, Jacob S and Majumder S: MicroRNA-221/222
confers tamoxifen resistance in breast cancer by targeting p27Kip1.
J Biol Chem. 283:29897–29903. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shen H, Zhu F, Liu J, Xu T, Pei D, Wang R,
Qian Y, Li Q, Wang L, Shi Z, et al: Alteration in Mir-21/PTEN
expression modulates gefitinib resistance in non-small cell lung
cancer. PLoS One. 9:e1033052014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ma H, Yao Q, Zhang AM, Lin S, Wang XX, Wu
L, Sun JG and Chen ZT: The effects of artesunate on the expression
of EGFR and ABCG2 in A549 human lung cancer cells and a xenograft
model. Molecules. 16:10556–10569. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mu XY, Dong XL, Sun J, Ni YH, Dong Z, Li
XL, Sun EL, Yi Z and Li G: Simultaneous blockage of epidermal
growth factor receptor and cyclooxygenase-2 in a human
xenotransplanted lung cancer model. Asian Pac J Cancer Prev.
15:69–73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guix M, Faber AC, Wang SE, Olivares MG,
Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, et al:
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer
cells is mediated by loss of IGF-binding proteins. J Clin Invest.
118:2609–2619. 2008.PubMed/NCBI
|
|
17
|
Choi YJ, Park GM, Rho JK, Kim SY, So GS,
Kim HR, Choi CM and Lee JC: Role of IGF-binding protein 3 in the
resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase
inhibitors. PLoS One. 8:e813932013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu LZ, Zhou XD, Qian G, Shi X, Fang J and
Jiang BH: AKT1 amplification regulates cisplatin resistance in
human lung cancer cells through the mammalian target of
rapamycin/p70S6K1 pathway. Cancer Res. 67:6325–6332. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Alexia C, Bras M, Fallot G, Vadrot N,
Daniel F, Lasfer M, Tamouza H and Groyer A: Pleiotropic effects of
PI-3′ kinase/Akt signaling in human hepatoma cell proliferation and
drug-induced apoptosis. Ann NY Acad Sci. 1090:1–17. 2006.
View Article : Google Scholar
|
|
20
|
Poh TW and Pervaiz S: LY294002 and
LY303511 sensitize tumor cells to drug-induced apoptosis via
intracellular hydrogen peroxide production independent of the
phosphoinositide 3-kinase-Akt pathway. Cancer Res. 65:6264–6274.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Brozovic A and Osmak M: Activation of
mitogen-activated protein kinases by cisplatin and their role in
cisplatin-resistance. Cancer Lett. 251:1–16. 2007. View Article : Google Scholar
|
|
22
|
Corradetti MN and Guan KL: Upstream of the
mammalian target of rapamycin: Do all roads pass through mTOR?
Oncogene. 25:6347–6360. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lekmine F, Uddin S, Sassano A, Parmar S,
Brachmann SM, Majchrzak B, Sonenberg N, Hay N, Fish EN and
Platanias LC: Activation of the p70 S6 kinase and phosphorylation
of the 4E-BP1 repressor of mRNA translation by type I interferons.
J Biol Chem. 278:27772–27780. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Donev IS, Wang W, Yamada T, Li Q, Takeuchi
S, Matsumoto K, Yamori T, Nishioka Y, Sone S and Yano S: Transient
PI3K inhibition induces apoptosis and overcomes HGF-mediated
resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer
Res. 17:2260–2269. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ogino A, Kitao H, Hirano S, Uchida A,
Ishiai M, Kozuki T, Takigawa N, Takata M, Kiura K and Tanimoto M:
Emergence of epidermal growth factor receptor T790M mutation during
chronic exposure to gefitinib in a non small cell lung cancer cell
line. Cancer Res. 67:7807–7814. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Engelman JA, Mukohara T, Zejnullahu K,
Lifshits E, Borrás AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun
J, et al: Allelic dilution obscures detection of a biologically
significant resistance mutation in EGFR-amplified lung cancer. J
Clin Invest. 116:2695–2706. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li H, Schmid-Bindert G, Wang D, Zhao Y,
Yang X, Su B and Zhou C: Blocking the PI3K/AKT and MEK/ERK
signaling pathways can overcome gefitinib-resistance in non-small
cell lung cancer cell lines. Adv Med Sci. 56:275–284. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Du L and Pertsemlidis A: microRNAs and
lung cancer: Tumors and 22-mers. Cancer Metastasis Rev. 29:109–122.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gibson NW: Engineered microRNA
therapeutics. J R Coll Physicians Edinb. 44:196–200. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li B, Ren S, Li X, Wang Y, Garfield D,
Zhou S, Chen X, Su C, Chen M, Kuang P, et al: MiR-21 overexpression
is associated with acquired resistance of EGFR-TKI in non-small
cell lung cancer. Lung Cancer. 83:146–153. 2014. View Article : Google Scholar
|
|
31
|
Kitamura K, Seike M, Okano T, Matsuda K,
Miyanaga A, Mizutani H, Noro R, Minegishi Y, Kubota K and Gemma A:
MiR-134/487b/655 cluster regulates TGF-β-induced
epithelial-mesenchymal transition and drug resistance to gefitinib
by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer Ther.
13:444–453. 2014. View Article : Google Scholar
|
|
32
|
Park KS, Raffeld M, Moon YW, Xi L, Bianco
C, Pham T, Lee LC, Mitsudomi T, Yatabe Y, Okamoto I, et al: CRIPTO1
expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor
resistance. J Clin Invest. 124:3003–3015. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang T, Zheng ZM, Li XN, Li ZF, Wang Y,
Geng YF, Bai L and Zhang XB: MiR-223 modulates multidrug resistance
via downregulation of ABCB1 in hepatocellular carcinoma cells. Exp
Biol Med (Maywood). 238:1024–1032. 2013. View Article : Google Scholar
|
|
34
|
Eto K, Iwatsuki M, Watanabe M, Ishimoto T,
Ida S, Imamura Y, Iwagami S, Baba Y, Sakamoto Y, Miyamoto Y, et al:
The sensitivity of gastric cancer to trastuzumab is regulated by
the miR-223/FBXW7 pathway. Int J Cancer. 136:1537–1545. 2015.
View Article : Google Scholar
|
|
35
|
Jia CY, Li HH, Zhu XC, Dong YW, Fu D, Zhao
QL, Wu W and Wu XZ: MiR-223 suppresses cell proliferation by
targeting IGF-1R. PLoS One. 6:e270082011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Allen GW, Saba C, Armstrong EA, Huang SM,
Benavente S, Ludwig DL, Hicklin DJ and Harari PM: Insulin-like
growth factor-I receptor signaling blockade combined with
radiation. Cancer Res. 67:1155–1162. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Atashpour S, Fouladdel S, Movahhed TK,
Barzegar E, Ghahremani MH, Ostad SN and Azizi E: Quercetin induces
cell cycle arrest and apoptosis in CD133(+) cancer stem cells of
human colorectal HT29 cancer cell line and enhances anticancer
effects of doxorubicin. Iran J Basic Med Sci. 18:635–643.
2015.PubMed/NCBI
|
|
38
|
Miki J, Furusato B, Li H, Gu Y, Takahashi
H, Egawa S, Sesterhenn IA, McLeod DG, Srivastava S and Rhim JS:
Identification of putative stem cell markers, CD133 and CXCR4, in
hTERT-immortalized primary nonmalignant and malignant tumor-derived
human prostate epithelial cell lines and in prostate cancer
specimens. Cancer Res. 67:3153–3161. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kim CK, Kim SK, Yang YH, Lee MS, Yoon JH
and Park CI: A case of recurrent infantile polycystic kidney
associated with hydrops fetalis. Yonsei Med J. 30:95–103. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Suda K, Murakami I, Katayama T, Tomizawa
K, Osada H, Sekido Y, Maehara Y, Yatabe Y and Mitsudomi T:
Reciprocal and complementary role of MET amplification and EGFR
T790M mutation in acquired resistance to kinase inhibitors in lung
cancer. Clin Cancer Res. 16:5489–5498. 2010. View Article : Google Scholar : PubMed/NCBI
|
